文献速递乳腺癌

西米普利单抗联合非拉利单抗加新辅助化疗治疗早期高危ERBB2阴性乳腺癌:I-SPY2随机临床试验

Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2026-01-01

I-SPY2平台试验将PD-1抑制剂西米普利单抗与抗LAG-3抗体非拉利单抗加入新辅助化疗,用于早期高危ERBB2阴性乳腺癌。干预组78例,历史对照组350例。结果显示PCF方案在所有临床特征中达标,总体pCR率44% vs 21%,三阴性53% vs 29%,HR阳性/ERBB2阴性36% vs 14%。21%患者发生肾上腺功能不全,包括11%的3-4级垂体炎,多发生于免疫治疗结束后。

要点

  • PCF方案在ERBB2阴性早期高危乳腺癌中显著提高pCR率,总体44% vs 21%。
  • 三阴性亚组pCR率53% vs 29%,HR阳性/ERBB2阴性亚组36% vs 14%。
  • 21%患者发生肾上腺功能不全,包括11%的3-4级垂体炎,需警惕免疫相关不良反应。

核心结论

  • PD-1联合抗LAG-3抑制加标准新辅助化疗在早期ERBB2阴性乳腺癌中有效,尤其在ImPrint免疫特征阳性患者中高度有效。
  • 结果值得进一步开展确定性试验。

研究设计与样本

  • I-SPY2是一项正在进行的随机临床平台试验,在美国多个临床中心开展,纳入早期(II或III期)ERBB2阴性高危乳腺癌患者。
  • 参与者自2010年起持续入组,于2020年2月2日至2021年12月9日根据HR、ERBB2状态和MammaPrint分子风险(MP1高或MP2超高)自适应随机分配至实验性新辅助治疗或对照组。
  • 干预组78例(平均年龄47岁),历史对照组350例(平均年龄48岁)。

主要发现

  • PCF在所有临床特征中达标,总体pCR率44%(95% CI, 34%-53%)vs 对照21%(95% CI, 17%-25%)。
  • 三阴性亚组pCR率53%(95% CI, 39%-67%)vs 29%(95% CI, 22%-36%)。
  • HR阳性/ERBB2阴性亚组pCR率36%(95% CI, 23%-49%)vs 14%(95% CI, 9%-19%)。
  • 21%患者(16例)发生肾上腺功能不全,包括11%的3-4级垂体炎,多发生于免疫治疗结束后。

关键数值与推荐

  • 治疗在亚型特异性3期试验中达到85%贝叶斯成功概率时毕业。
  • PCF方案在所有临床特征中毕业。

临床怎么用

  • 对于早期高危ERBB2阴性乳腺癌,可考虑在标准新辅助化疗基础上联合PD-1和抗LAG-3双免疫检查点 blockade,尤其ImPrint免疫特征阳性者。
  • 治疗期间及结束后需监测肾上腺功能不全和垂体炎等免疫相关不良反应。

局限性

  • 对照组为历史对照人群,非同期随机对照。
  • 样本量有限,需进一步确定性试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Although adding immune checkpoint inhibitors to neoadjuvant chemotherapy improves outcomes in high-risk early-stage breast cancer, opportunities remain to further enhance response. Dual checkpoint blockade offers a potential strategy to further enhance efficacy. OBJECTIVE: To evaluate the combination of anti-programmed cell death 1 protein (PD-1) cemiplimab and anti-lymphocyte activation gene 3 (LAG-3) added to neoadjuvant therapy in ERBB2-negative early-stage, high-risk breast cancer. DESIGN, SETTING, AND PARTICIPANTS: The I-SPY2 (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging and Molecular Analysis 2) is an ongoing randomized clinical platform trial being conducted at multiple US clinical sites including patients with early-stage (II or III) ERBB2-negative, high-risk breast cancer. Participants, continuously enrolled since 2010, were adaptively randomized from February 2, 2020, to December 9, 2021, to one of several experimental neoadjuvant therapies or control groups based on receptor subtypes defined by hormone receptor (HR), ERBB2 status, and MammaPrint (Agendia Inc) molecular risk, categorized as high (MP1) or ultrahigh (MP2). Data were analyzed from January 1, 2022, to August 5, 2025. INTERVENTIONS: Both groups received weekly paclitaxel for 12 weeks, then doxorubicin and cyclophosphamide followed by surgery; concomitant with paclitaxel, the intervention group also received 4 doses of cemiplimab and fianlimab (PCF) every 3 weeks. MAIN OUTCOMES AND MEASURES: Pathologic complete response (pCR). Treatments graduated when they achieved 85% bayesian probability of success in a subtype-specific phase 3 trial. Pathway-specific biomarkers were assessed for response prediction. RESULTS: A total of 78 participants (mean [SD] age, 47 [39-54] years) were randomized to the intervention group, with 350 participants (mean [SD] age, 48 [39-57] years) randomized to the historical control population. PCF graduated in all clinical signatures, with pCR rates vs control of 44% (95% CI, 34%-53%) vs 21% (95% CI, 17%-25%) in all ERBB2, 53% (95% CI, 39%-67%) vs 29% (95% CI, 22%-36%) in triple-negative, and 36% (95% CI, 23%-49%) vs 14% (95% CI, 9%-19%) in HR-positive and ERBB2-negative disease. Among the total participants, 16 (21%) experienced adrenal insufficiency, including hypophysitis (11% grade 3 or 4), mostly occurring after immunotherapy completion. PCF was found to be highly effective in the subset of patients with immune signature positive status (ImPrint positive). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, the combination of PD-1 and anti-LAG-3 inhibition with standard NAC was effective in early-stage ERBB2-negative breast cancer, particularly in patients displaying a positive ImPrint immune signature. These results warrant further definitive trials. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01042379.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Isaacs C, Nanda R, Yau C, et al. Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial. JAMA Oncol. 2026. PMID: 42530945. doi:10.1001/jamaoncol.2026.2576

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。